CD40 and neoplasm: To prepare rWTC-MBTA-Vax, (i) autologous or syngeneic cancer cells are irradiated so that it remains alive but non-replicative, (ii) irradiated cells are combined with mannan-BAM and TLR agonists, along with anti-CD40 antibody, to produce the effective vaccine, and (iii) the prepared rWTC-MBTA is injected peripherally over four weeks to propagate a tumor-specific immune response to inhibit tumor or cancerous growth, metastasis, and prevent recurrence (199, 200).